间充质干细胞治疗炎症性肠病的应用及前景

Application and prospect of mesenchymal stem cells in treatment of inflammatory bowel disease

炎症性肠病(IBD)是一种慢性非特异性肠道炎性疾病,其病因未明,有终生复发倾向,重症者迁延不愈。早期治疗以药物为主,部分重症患者后期需要手术干预。近年来,间充质干细胞(MSCs)由于具有多向分化潜能、免疫调节及组织修复功能已被广泛应用于IBD治疗的临床前基础研究中,具有一定理论基础。在已开展的MSCs治疗IBD的临床试验中,尚未有严重并发症的报道。虽然目前MSCs治疗不是IBD的标准治疗方案,但今后可能会成为一种新的治疗选择,特别是对于难治性或合并肛瘘的IBD患者。本文就MSCs的概况及其在IBD治疗的作用机制和应用前景作一综述。

Inflammatory bowel disease(IBD)is a chronic non-specific intestinal inflammatory disease,with unknown aetiology.There is a tendency to relapse throughout the life of patients with IBD and the severe cases cannot be cured.Early treatment is based on drugs,and some severe patients require surgical intervention later.In recent years,mesenchymal stem cells(MSCs)have been widely used in the experimental research of IBD treatment due to their multi-directional differentiation potential,immune regulation and tissue repair function,and it has a certain theoretical basis.In some clinical trials of MSCs for the treatment of IBD,there no serious complications have been reported and a certain therapeutic effect has been found.Currently,such stem cell therapy is not a standard of treatment regimen for IBD.However,it may potentially become a new option,especially for the IBD which is refractory or complicated with anal fistula.The purpose of this review article is to summarize the basic characteristics of MSCs,demonstrate the mechanism and application of MSCs in the therapy of IBD and prospect its trend in the future.